CMPX
Compass Therapeutics, Inc.
Price Chart
Latest Quote
$2.05
+0.08 (+4.06%)
Current Price
| Previous Close | $1.97 |
| Open | $1.99 |
| Day High | $2.14 |
| Day Low | $1.99 |
| Volume | 3,473,378 |
Stock Information
| Shares Outstanding | 180.09M |
| Total Debt | $9.79M |
| Cash Equivalents | $194.69M |
| Net Income | $-68.17M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $363.78M |
| EPS (TTM) | $-0.40 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $169.88M |
| Income | $-68.17M |
| Book/sh | $1.03 |
| Cash/sh | $1.08 |
| Employees | 39 |
Financial Ratios
| Quick Ratio | 18.94 |
| Current Ratio | 19.04 |
| Debt/Eq | 5.25 |
Returns & Margins
| ROA | -27.91% |
| ROE | -45.95% |
Ownership
| Insider Ownership | 12.46% |
| Institutional Ownership | 94.09% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -4.39 |
| P/B | 1.95 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $8.82 |
Technical Indicators
| SMA20 | $2.10 |
| SMA50 | $2.83 |
| SMA200 | $4.43 |
| RSI | 30.85 |
| ATR | 0.1215 |
| Shares Float | 122.69M |
| Short Float | 22.08% |
| Short Ratio | 4.31 |
| Volatility | 0.74 |
| Rel Volume | 2.10 |
Performance History
| Week | +0.50% |
| Month | +11.60% |
| Quarter | -62.52% |
| 6 Months | -61.45% |
| YTD | -60.93% |
| Year | -7.76% |
| 3 Years | -38.60% |
| 5 Years | -62.94% |
| 10 Years | -76.24% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $2.02 | 9,276,500 |
| 2026-06-17 | $2.05 | 3,744,500 |
| 2026-06-16 | $1.97 | 2,532,700 |
| 2026-06-15 | $2.04 | 2,174,800 |
| 2026-06-12 | $2.03 | 2,041,100 |
| 2026-06-11 | $2.01 | 3,589,300 |
| 2026-06-10 | $1.92 | 3,521,700 |
| 2026-06-09 | $2.06 | 2,327,300 |
| 2026-06-08 | $2.02 | 2,268,000 |
| 2026-06-05 | $2.04 | 3,144,400 |
| 2026-06-04 | $2.13 | 4,479,000 |
| 2026-06-03 | $2.10 | 3,509,000 |
| 2026-06-02 | $2.08 | 5,190,000 |
| 2026-06-01 | $2.22 | 5,709,000 |
| 2026-05-29 | $2.38 | 6,046,700 |
| 2026-05-28 | $2.41 | 4,832,200 |
| 2026-05-27 | $2.27 | 6,726,100 |
| 2026-05-26 | $2.20 | 4,725,200 |
| 2026-05-22 | $2.07 | 5,945,500 |
| 2026-05-21 | $1.93 | 6,576,800 |
| 2026-05-20 | $1.89 | 3,810,400 |
| 2026-05-19 | $1.81 | 3,731,800 |
About Compass Therapeutics, Inc.
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
đ° Latest News
How Compass Therapeutics (CMPX) Is Moving Tovecimig Toward a Potential Biliary Tract Cancer Filing
Insider Monkey âĸ 2026-06-17T15:16:31Z
Compass Therapeutics Eyes FDA Path After Tovecimig Trial Win
MarketBeat âĸ 2026-06-08T13:06:15Z
Compass Therapeutics (CMPX) Reports Q1 2026 Net Loss of $18.3M
Insider Monkey âĸ 2026-05-18T04:50:05Z
Canaccord Maintains Buy Rating on Compass Therapeutics (CMPX)
Insider Monkey âĸ 2026-05-05T12:16:53Z
Does Compass Therapeutics' (CMPX) Biliary Cancer Data Hint At A Broader Pipeline ReâRating Opportunity?
Simply Wall St. âĸ 2026-04-29T11:04:58Z
Micron initiated, Rambus downgraded: Wall Street's top analyst calls
The Fly âĸ 2026-04-28T14:19:52Z
Compass Therapeuticsâs stock crashes after OS miss in BTC trial
Clinical Trials Arena âĸ 2026-04-28T11:21:59Z
Midday Fly By: Verizon reports âbeat and raise,â Shell to acquire ARC
TipRanks âĸ 2026-04-28T00:01:56Z
Compass Therapeutics Touts âStunningâ PFS Win in COMPANION-002 as Crossover Muddy OS Data
MarketBeat âĸ 2026-04-27T20:42:04Z
This Biotech Stock Is Down 65%. How a Cancer Trial Was Ruined by Its Own Design.
Barrons.com âĸ 2026-04-27T19:19:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $850,000 | $0 | $0 |
| Operating Revenue | $0 | $850,000 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $72,839,000 | $57,475,000 | $50,363,000 | $41,655,000 |
| Other Income Expense | $-50,000 | $-50,000 | $-31,000 | $70,000 |
| Other Non Operating Income Expenses | $-50,000 | $-50,000 | $-31,000 | - |
| Net Non Operating Interest Income Expense | $6,400,000 | $7,300,000 | $7,900,000 | $2,360,000 |
| Operating Expense | $72,839,000 | $57,475,000 | $50,363,000 | $41,655,000 |
| General And Administrative Expense | $16,870,000 | $15,133,000 | $12,243,000 | $11,658,000 |
| Interest Expense | - | - | - | $0 |
| Interest Expense Non Operating | - | - | - | $0 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-66,489,000 | $-49,375,000 | $-42,494,000 | $-39,225,000 |
| Net Interest Income | $6,400,000 | $7,300,000 | $7,900,000 | $2,360,000 |
| Interest Income | $6,400,000 | $7,300,000 | $7,900,000 | $2,360,000 |
| Normalized Income | $-66,489,000 | $-49,375,000 | $-42,494,000 | $-39,295,000 |
| Net Income From Continuing And Discontinued Operation | $-66,489,000 | $-49,375,000 | $-42,494,000 | $-39,225,000 |
| Total Operating Income As Reported | $-72,839,000 | $-56,625,000 | $-50,363,000 | $-41,655,000 |
| Net Income Common Stockholders | $-66,489,000 | $-49,375,000 | $-42,494,000 | $-39,225,000 |
| Net Income | $-66,489,000 | $-49,375,000 | $-42,494,000 | $-39,225,000 |
| Net Income Including Noncontrolling Interests | $-66,489,000 | $-49,375,000 | $-42,494,000 | $-39,225,000 |
| Net Income Continuous Operations | $-66,489,000 | $-49,375,000 | $-42,494,000 | $-39,225,000 |
| Pretax Income | $-66,489,000 | $-49,375,000 | $-42,494,000 | $-39,225,000 |
| Interest Income Non Operating | $6,400,000 | $7,300,000 | $7,900,000 | $2,360,000 |
| Operating Income | $-72,839,000 | $-56,625,000 | $-50,363,000 | $-41,655,000 |
| Special Income Charges | - | - | $0 | $70,000 |
| Per Share | ||||
| Diluted EPS | $-0.42 | $-0.36 | $-0.33 | $-0.37 |
| Basic EPS | $-0.42 | $-0.36 | $-0.33 | $-0.37 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-71,367,000 | $-54,872,000 | $-48,473,000 | $-39,821,000 |
| Reconciled Depreciation | $1,472,000 | $1,753,000 | $1,890,000 | $1,904,000 |
| EBITDA (Bullshit earnings) | $-71,367,000 | $-54,872,000 | $-48,473,000 | $-39,751,000 |
| EBIT | $-72,839,000 | $-56,625,000 | $-50,363,000 | $-41,655,000 |
| Diluted Average Shares | $157,695,000 | $137,152,778 | $127,027,000 | $105,186,000 |
| Basic Average Shares | $157,695,000 | $137,152,778 | $127,027,000 | $105,186,000 |
| Diluted NI Availto Com Stockholders | $-66,489,000 | $-49,375,000 | $-42,494,000 | $-39,225,000 |
| Research And Development | $55,969,000 | $42,342,000 | $38,120,000 | $29,997,000 |
| Selling General And Administration | $16,870,000 | $15,133,000 | $12,243,000 | $11,658,000 |
| Other Gand A | $16,870,000 | $15,133,000 | $12,243,000 | $11,658,000 |
| Tax Provision | - | $0 | $0 | $0 |
| Total Unusual Items | - | - | $0 | $70,000 |
| Total Unusual Items Excluding Goodwill | - | - | $0 | $70,000 |
| Gain On Sale Of Ppe | - | - | $0 | $70,000 |
| Other Special Charges | - | - | - | - |
Fetched: 2026-06-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $196,791,000 | $125,233,000 | $148,538,000 | $181,638,000 |
| Total Assets | $219,588,000 | $140,403,000 | $156,875,000 | $199,645,000 |
| Total Non Current Assets | $9,769,000 | $7,652,000 | $2,994,000 | $4,854,000 |
| Other Non Current Assets | $568,000 | $568,000 | $320,000 | $320,000 |
| Current Assets | $209,819,000 | $132,751,000 | $153,881,000 | $194,791,000 |
| Other Current Assets | $913,000 | $6,029,000 | $1,420,000 | $8,182,000 |
| Cash Cash Equivalents And Short Term Investments | $208,906,000 | $126,722,000 | $152,461,000 | $186,609,000 |
| Cash And Cash Equivalents | $30,643,000 | $43,483,000 | $24,228,000 | $34,946,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $9,829,000 | $6,634,000 | $1,733,000 | $2,935,000 |
| Long Term Debt And Capital Lease Obligation | $8,829,000 | $6,296,000 | $536,000 | $1,838,000 |
| Current Debt And Capital Lease Obligation | $1,000,000 | $338,000 | $1,197,000 | $1,097,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $22,797,000 | $15,170,000 | $8,337,000 | $18,007,000 |
| Total Non Current Liabilities Net Minority Interest | $8,829,000 | $6,296,000 | $536,000 | $1,838,000 |
| Current Liabilities | $13,968,000 | $8,874,000 | $7,801,000 | $16,169,000 |
| Payables And Accrued Expenses | $10,286,000 | $5,743,000 | $4,666,000 | $13,516,000 |
| Payables | $1,585,000 | $2,249,000 | $4,090,000 | $3,382,000 |
| Accounts Payable | $1,585,000 | $2,249,000 | $4,090,000 | $3,382,000 |
| Other Non Current Liabilities | - | $1,000 | - | - |
| Equity | ||||
| Common Stock Equity | $196,791,000 | $125,233,000 | $148,538,000 | $181,638,000 |
| Total Equity Gross Minority Interest | $196,791,000 | $125,233,000 | $148,538,000 | $181,638,000 |
| Stockholders Equity | $196,791,000 | $125,233,000 | $148,538,000 | $181,638,000 |
| Gains Losses Not Affecting Retained Earnings | $280,000 | $210,000 | $37,000 | $-302,000 |
| Other Equity Adjustments | $280,000 | $210,000 | $37,000 | $-302,000 |
| Retained Earnings | $-431,172,000 | $-364,683,000 | $-315,308,000 | $-272,814,000 |
| Other | ||||
| Ordinary Shares Number | $178,324,000 | $137,820,000 | $127,668,000 | $126,302,000 |
| Share Issued | $178,324,000 | $137,820,000 | $127,668,000 | $126,302,000 |
| Tangible Book Value | $196,791,000 | $125,233,000 | $148,538,000 | $181,638,000 |
| Invested Capital | $196,791,000 | $125,233,000 | $148,538,000 | $181,638,000 |
| Working Capital | $195,851,000 | $123,877,000 | $146,080,000 | $178,622,000 |
| Capital Lease Obligations | $9,829,000 | $6,634,000 | $1,733,000 | $2,935,000 |
| Total Capitalization | $196,791,000 | $125,233,000 | $148,538,000 | $181,638,000 |
| Additional Paid In Capital | $627,665,000 | $489,692,000 | $463,796,000 | $454,741,000 |
| Capital Stock | $18,000 | $14,000 | $13,000 | $13,000 |
| Common Stock | $18,000 | $14,000 | $13,000 | $13,000 |
| Long Term Capital Lease Obligation | $8,829,000 | $6,296,000 | $536,000 | $1,838,000 |
| Current Capital Lease Obligation | $1,000,000 | $338,000 | $1,197,000 | $1,097,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $2,682,000 | $2,793,000 | $1,938,000 | $1,556,000 |
| Current Accrued Expenses | $8,701,000 | $3,494,000 | $576,000 | $10,134,000 |
| Net PPE | $9,201,000 | $7,084,000 | $2,674,000 | $4,534,000 |
| Accumulated Depreciation | $-6,637,000 | $-6,361,000 | $-6,267,000 | $-5,568,000 |
| Gross PPE | $15,838,000 | $13,445,000 | $8,941,000 | $10,102,000 |
| Leases | $1,612,000 | $1,612,000 | $1,612,000 | $1,612,000 |
| Other Properties | $13,840,000 | $11,447,000 | $6,943,000 | $8,104,000 |
| Machinery Furniture Equipment | $386,000 | $386,000 | $386,000 | $386,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $178,263,000 | $83,239,000 | $128,233,000 | $151,663,000 |
| Treasury Shares Number | - | - | - | - |
| Preferred Stock | - | - | - | - |
Fetched: 2026-06-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-49,168,000 | $-44,899,000 | $-40,648,000 | $-34,337,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-49,143,000 | $-44,855,000 | $-40,618,000 | $-34,125,000 |
| Cash Flow From Continuing Operating Activities | $-49,143,000 | $-44,855,000 | $-40,618,000 | $-34,125,000 |
| Operating Gains Losses | - | - | - | $-70,000 |
| Investing Activities | ||||
| Capital Expenditure | $-25,000 | $-44,000 | $-30,000 | $-212,000 |
| Investing Cash Flow | $-93,306,000 | $46,772,000 | $26,965,000 | $-151,200,000 |
| Cash Flow From Continuing Investing Activities | $-93,306,000 | $46,772,000 | $26,965,000 | $-151,200,000 |
| Net Other Investing Changes | - | - | - | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $137,999,000 | $18,113,000 | $3,126,000 | $76,237,000 |
| Financing Cash Flow | $129,609,000 | $17,338,000 | $2,935,000 | $75,757,000 |
| Cash Flow From Continuing Financing Activities | $129,609,000 | $17,338,000 | $2,935,000 | $75,757,000 |
| Net Other Financing Charges | $-9,665,000 | $-775,000 | $-253,000 | $-495,000 |
| Net Common Stock Issuance | $137,999,000 | $18,113,000 | $3,126,000 | $76,237,000 |
| Common Stock Issuance | $137,999,000 | $18,113,000 | $3,126,000 | $76,237,000 |
| Other | ||||
| End Cash Position | $31,211,000 | $43,483,000 | $24,228,000 | $34,946,000 |
| Beginning Cash Position | $44,051,000 | $24,228,000 | $34,946,000 | $144,514,000 |
| Changes In Cash | $-12,840,000 | $19,255,000 | $-10,718,000 | $-109,568,000 |
| Proceeds From Stock Option Exercised | $1,275,000 | $0 | $62,000 | $15,000 |
| Net Investment Purchase And Sale | $-93,281,000 | $46,816,000 | $26,995,000 | $-151,164,000 |
| Sale Of Investment | $101,276,000 | $134,974,000 | $182,413,000 | $48,955,000 |
| Purchase Of Investment | $-194,557,000 | $-88,158,000 | $-155,418,000 | $-200,119,000 |
| Net PPE Purchase And Sale | $-25,000 | $-44,000 | $-30,000 | $-36,000 |
| Purchase Of PPE | $-25,000 | $-44,000 | $-30,000 | $-212,000 |
| Change In Working Capital | $9,179,000 | $-4,142,000 | $-2,908,000 | $-1,263,000 |
| Change In Other Current Liabilities | $-369,000 | $-1,217,000 | $-1,202,000 | $-1,102,000 |
| Change In Payables And Accrued Expense | $4,432,000 | $1,932,000 | $-8,468,000 | $5,430,000 |
| Change In Accrued Expense | $5,096,000 | $3,773,000 | $-9,176,000 | $2,915,000 |
| Change In Payable | $-664,000 | $-1,841,000 | $708,000 | $2,515,000 |
| Change In Account Payable | $-664,000 | $-1,841,000 | $708,000 | $2,515,000 |
| Change In Prepaid Assets | $5,116,000 | $-4,857,000 | $6,762,000 | $-5,591,000 |
| Stock Based Compensation | $8,368,000 | $8,560,000 | $6,120,000 | $5,330,000 |
| Amortization Of Securities | $-1,673,000 | $-1,651,000 | $-3,226,000 | $-801,000 |
| Depreciation Amortization Depletion | $1,472,000 | $1,753,000 | $1,890,000 | $1,904,000 |
| Depreciation And Amortization | $1,472,000 | $1,753,000 | $1,890,000 | $1,904,000 |
| Depreciation | $1,472,000 | $1,753,000 | $1,890,000 | $1,904,000 |
| Net Income From Continuing Operations | $-66,489,000 | $-49,375,000 | $-42,494,000 | $-39,225,000 |
| Sale Of PPE | - | - | $0 | $176,000 |
| Gain Loss On Sale Of PPE | - | - | $0 | $-70,000 |
| Repayment Of Debt | - | - | - | $0 |
| Interest Paid Supplemental Data | - | - | - | $0 |
| Net Issuance Payments Of Debt | - | - | - | $0 |
| Net Long Term Debt Issuance | - | - | - | $0 |
| Long Term Debt Payments | - | - | - | $0 |
| Asset Impairment Charge | - | - | - | $0 |
| Change In Other Current Assets | - | - | - | - |
| Other Non Cash Items | - | - | - | - |
Fetched: 2026-06-17